SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

MAZE

Maze Therapeutics Inc.
NASDAQHealth Care

Latest close: 27.53 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 16, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Oct 1, 2026Reported sale · Form 4Jason Coloma V, Chief Executive Officer · $70.1KOpen the filing ↗
  3. Oct 1, 2026Reported sale · Form 4Jason Coloma V, Chief Executive Officer · $862.2KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record20120 flagged findings
Reported transactions (Form 4)80since Mar 2, 2026 · and 40 other holdings
Corporate events (8-K)12since Sep 2, 2025

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-12share offering or dilution eventrecentOpen filing ↗
    “…Commission, or SEC, which allows us to sell any combination of common stock, preferred stock, debt securities, warrants,…”
    +1 more passage from the same document
    • “…pursuant to which we issued and sold an aggregate of 5,540,000 shares of our common stock at $23.50 per share and pre-funded…”
  • 2026-05-12export control restrictionsrecentOpen filing ↗
    “…actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what…”
  • 2026-05-12capital return (buybacks/dividends)recentOpen filing ↗
    “…31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025 — — Common stock, $ 0.001…”
    +1 more passage from the same document
    • “…net loss per share attributable to common stockholders for the periods presented because including them would have been…”
  • 2026-05-12Department of Justice inquiryrecentOpen filing ↗
    “…and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain…”
  • 2026-04-22share offering or dilution eventrecentOpen filing ↗
    “…of (a) 5,540,000 shares of its common stock (the “ Shares ”) and (b) pre-funded warrants to purchase 850,000 shares of its common…”
    +1 more passage from the same document
    • “…(the “ Pre-Funded Warrants ”) to the Underwriter (the “ Offering ”). The Shares will be sold at the offering price of $23.50 per…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 201)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 16, 268-K ↗Current report · Entered a material agreement new
  • Insider transaction · 3 Form 4 filingsshow all 3hide
  • Notice of proposed sale · 2 Form 144 filingsshow all 2hide
  • Insider transaction · 3 Form 4 filingsshow all 3hide
  • Sep 4, 26Form 144 ↗Notice of proposed sale
  • Insider transaction · 6 Form 4 filingsshow all 6hide
  • Notice of proposed sale · 5 Form 144 filingsshow all 5hide
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Aug 17, 26Form 3 ↗Insider transaction
  • Aug 17, 26Form 4 ↗Insider transaction

201 filings on record, the oldest from Jul 25, 24.

Listing the 25 most recent filings of the 201 on record.

8-Ks, explained

Structure7Governance5
  • Oct 16, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Governance3 senior executive changes2026show all 3hide
    • Aug 17, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • May 22, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Mar 25, 26GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
  • Feb 4, 26StructureA material agreement was terminated+2 more in the same filing8-K 1.02 ↗
  • Oct 6, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Sep 11, 25StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Sep 2, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • James N. Topper10.2%Apr 25, 25SCHEDULE 13G/A ↗17 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Third Rock Ventures IV, L.P.9.3%Dec 31, 25SCHEDULE 13G/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
  • Deep Track Capital, LP9.0%Jun 30, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Frazier Life Sciences Public Fund, L.P.9.0%Dec 31, 25SCHEDULE 13G/A ↗14 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Paradigm BioCapital Advisors LP6.1%Mar 25, 26SCHEDULE 13G ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
show 5 more holdershide
  • JANUS HENDERSON GROUP PLC5.8%Mar 31, 26SCHEDULE 13G/A ↗1 earlier filing
  • BlackRock, Inc.5.4%Jun 30, 26SCHEDULE 13G ↗
  • Matrix Capital Management Company, LP3.5%Sep 30, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Alphabet Holdings LLC2.9%Dec 31, 25SCHEDULE 13G/A ↗9 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • James Tananbaum1.4%Sep 30, 25SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Oct 1, Coloma Jason V filed notice of intent to sell up to $933K. That is about 0.06% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $932K across 2 trades on Oct 1, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

View notice (Form 144) ↗+9 more recent notices · 9 with a later sale

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Oct 1, 26Sell$70KJason Coloma VChief Executive Officer↗
  • Oct 1, 26Sell$862KJason Coloma VChief Executive Officer↗
  • Oct 1, 26Sell$435KHarold BernsteinPresident, R&D & CMO↗
  • Sep 29, 26Sell$203KAtul DandekarCSBO↗
  • Sep 4, 26Sell$255KHarold BernsteinPresident, R&D & CMO↗
  • Sep 3, 26Sell$293KJason Coloma VChief Executive Officer↗
  • Sep 3, 26Sell$3KJason Coloma VChief Executive Officer↗
  • Sep 3, 26Sell$52KPhillips CourtneyGC and Corp. Secretary↗
  • Sep 3, 26Sell$567Phillips CourtneyGC and Corp. Secretary↗
  • Sep 3, 26Sell$83KAtul DandekarCSBO↗
  • Sep 3, 26Sell$929Atul DandekarCSBO↗
  • Sep 3, 26Sell$133KHarold BernsteinPresident, R&D & CMO↗

There are 18 more transactions in this stretch.

Stock compensation, tax and giftsshow the 10 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Oct 1, 26Compensation$168KHarold BernsteinPresident, R&D & CMO↗
  • Sep 29, 26Compensation$78KAtul DandekarCSBO↗
  • Sep 1, 26Compensationamount n/aJason Coloma VChief Executive Officer↗
  • Sep 1, 26Compensationamount n/aPhillips CourtneyGC and Corp. Secretary↗
  • Sep 1, 26Compensationamount n/aAtul DandekarCSBO↗
  • Sep 1, 26Compensation$168KHarold BernsteinPresident, R&D & CMO↗
  • Sep 1, 26Compensationamount n/aHarold BernsteinPresident, R&D & CMO↗
  • Aug 28, 26Compensation$78KAtul DandekarCSBO↗
  • Aug 13, 26Compensation$168KHarold BernsteinPresident, R&D & CMO↗
  • Jul 29, 26Compensation$78KAtul DandekarCSBO↗

The full record holds 154 transactions and goes back to Nov 26, 24.

Its sector and its market

Maze Therapeutics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Maze Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Maze Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
201 documents on file, from Jul 25, 2024 to Oct 16, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.